Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.
The US drug regulator has granted accelerated approval for a drug to treat chronic inflammatory liver disease to Genfit, headquartered in Nord, France,.
Fifteen member states of the European Union and the European Economic Area will procure up to 40 million doses of avian influenza virus.
A four-year-old child in India has been detected with avian influenza A(H9N2) in the Eastern state of West Bengal, the World Health Organization.
A 59-year-old person in Mexico died in April after contracting avian influenza A(H5N2) virus, the first such death in the country, according to.
The advisory committee of the US Food and Drug Administration has rejected a therapy using party drug MDMA, or ecstasy or molly to.
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.
Researchers at the National Institutes of Health have developed an artificial intelligence tool that uses a simple blood test to predict if cancer.
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.